Last reviewed · How we verify
Pneumococcal Polysaccharide Conjugate Vaccine
Pneumococcal Polysaccharide Conjugate Vaccine is a Biologic drug developed by PATH. It is currently in Phase 2 development. Also known as: PNEUMOSIL.
At a glance
| Generic name | Pneumococcal Polysaccharide Conjugate Vaccine |
|---|---|
| Also known as | PNEUMOSIL |
| Sponsor | PATH |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Influence of Methotrexate Discontinuation on Immunogenicity After PCV-20 Vaccine in Patients ARDs (PHASE4)
- Dose-Ranging Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine (PHASE2)
- A Clinical Study of the V116 Vaccine for Children and Teenagers (V116-013) (PHASE3)
- Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS (PHASE3)
- Safety and Immunogenicity of PCV20 in Pediatric Patients With Autoimmune Rheumatic Diseases (PHASE4)
- Safety and Immunogenicity of V116 in Adults With Increased Risk for Pneumococcal Disease (V116-008) (PHASE3)
- Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 50 Years of Age or Older (V116-010, STRIDE-10) (PHASE3)
- A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pneumococcal Polysaccharide Conjugate Vaccine CI brief — competitive landscape report
- Pneumococcal Polysaccharide Conjugate Vaccine updates RSS · CI watch RSS
- PATH portfolio CI
Frequently asked questions about Pneumococcal Polysaccharide Conjugate Vaccine
What is Pneumococcal Polysaccharide Conjugate Vaccine?
Pneumococcal Polysaccharide Conjugate Vaccine is a Biologic drug developed by PATH.
Who makes Pneumococcal Polysaccharide Conjugate Vaccine?
Pneumococcal Polysaccharide Conjugate Vaccine is developed by PATH (see full PATH pipeline at /company/path).
Is Pneumococcal Polysaccharide Conjugate Vaccine also known as anything else?
Pneumococcal Polysaccharide Conjugate Vaccine is also known as PNEUMOSIL.
What development phase is Pneumococcal Polysaccharide Conjugate Vaccine in?
Pneumococcal Polysaccharide Conjugate Vaccine is in Phase 2.
Related
- Manufacturer: PATH — full pipeline
- Also known as: PNEUMOSIL
- Compare: Pneumococcal Polysaccharide Conjugate Vaccine vs similar drugs
- Pricing: Pneumococcal Polysaccharide Conjugate Vaccine cost, discount & access